Eric Halioua, President & CEO of PDC*line Pharma will be a panelist in the Advances in Cell & Gene Therapies round table at the 11th Annual European Life Sciences CEO Forum. A Sachs Associates event organized, Feb. 27, 2018 in Hilton Zurich Airport Hotel (Switzerland).

PDC*line Pharma CMO and CSO will be present at ESMO Immuno Oncology Congress in Geneva, Switzerland – 07 Dec – 10 Dec 2017. A poster will be presented describing our last results with Neo-Antigens. Title of the abstract is: “PDC*vac: a powerful platform for priming and expanding Neo-Antigen specific-T cells”.

There is a paradigm shift in the treatment of cancer with recent research demonstrating that the immune system has tremendous potential to destroy tumours. Is immuno-oncology the new era of cancer medicine?

Eric Halioua, CEO of PDC*line Pharma will be speaker at an official satellite workshop at BIO US (San Diego, CA – US) to present the company strategy for new immunotherapies. The workshop entitled “Will Immunotherapy cure Cancer? Experts Unravel the New Gold Rush” is organized 19 June 2017, 8.30 am – 1.00 pm at The Westgate Hotel. Pioneers in Cancer Immunotherapy will share vital insights:

  • Why is immunotherapy more than the latest hype?
  • How to tackle challenges and avoid pitfalls?
  • How to close a major pharma-deal?

Book now: http://www.essenscia.be/en/Calendar/Registration/399

We are very pleased to inform you that the 8th edition of MATWIN’s international board has awarded PDC*line Pharma with the prize of most promising project in the “start-up” category.

 

This prize confirms the value of our project and development plan. The International Board of MATWIN meets once a year to audition the best selected projects in oncology, to make recommendations and to label those that it considers with the greatest potential for development. This Board brings together academic Key Opinion Leaders in oncology from the largest research institutes in Europe and international leaders of R & D Oncology departments from pharmaceutical companies. For the first time this year, MATWIN also invited two representatives of venture capital funds (Kurma Partners and Sofinnova Partners) to participate in its Board.

 

Please find enclosed the list of the board members. For more information, please click on the link: http://www.matwin.fr/matwin/actors_involved/international_board-p14.html

 

MATWIN – Maturation & accelerating translation with industry – is a nationwide service platform which is unique in Europe and that supports the maturation of research projects in oncology up to the pre-clinical proof of concept. The program identifies world-class projects to accelerate their transfer from bench to the bedside. MATWIN thus helps promoting French research by furthering innovation and public-private partnerships. MATWIN is supported by eleven of the world’s largest pharmaceutical companies (AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi) and by the French Cancéropôles network.